We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dual HER2 Targeting in the Adjuvant Setting.
- Authors
Copeland, Anureet C.; Anders, Carey K.
- Abstract
Adjuvant human epidermal growth factor receptor 2 (HER2)-directed treatment has changed dramatically over the past decade. Historically, the addition of 1 year of trastuzumab to adjuvant chemotherapy has significantly improved both disease-free survival and overall survival across several studies. More recently, and in the metastatic setting, dual HER2-targeted therapy--beyond that of trastuzumab alone, and in combination with monoclonal antibodies such as pertuzumab and tyrosine kinase inhibitors such as lapatinib-- has shown a survival benefit. As is common in drug development, promising agents in the metastatic setting are then examined in the curative setting. This article will provide an overview of the efficacy of dual HER2-targeted therapy in the adjuvant setting as reported in the APHINITY ExteNET, and ALTTO trials. Potential toxicities with dual HER2-targeted therapy and the financial consequences of adding additional HER2-targeted therapy, beyond trastuzumab, in the adjuvant setting will also be discussed.
- Subjects
THERAPEUTIC use of monoclonal antibodies; PROTEIN-tyrosine kinase inhibitors; TUMOR treatment; TRASTUZUMAB; TUMOR prognosis; COMBINED modality therapy; EPIDERMAL growth factor; METASTASIS; ONCOGENES; SURVIVAL; THERAPEUTICS
- Publication
Oncology (08909091), 2018, Vol 32, Issue 10, p483
- ISSN
0890-9091
- Publication type
Article